本文已被：浏览 33次 下载 17次
投稿时间：2024-10-15 网络发布日期：2025-01-20
投稿时间：2024-10-15 网络发布日期：2025-01-20
中文摘要: 抗反转录病毒治疗（ART）显著改善了HIV/AIDS患者的预后，已成为全球防控AIDS的重要策略。然而，随着ART的广泛应用，HIV耐药问题逐渐突出，成为临床治疗的主要挑战。本文回顾了HIV耐药的流行现状和管理策略，重点探讨了蛋白酶抑制剂（PI）和新一代整合酶抑制剂（INSTI）在二线治疗中的应用。
Abstract:Antiretroviral therapy (ART) has significantly improved the prognosis of HIV/AIDS patients and has become an important global strategy for the prevention and control of AIDS. However, with the widespread use of ART, the resistance of HIV drug has gradually become the prominent problem and a major clinical challenge. This article reviews the current status of the prevalence of HIV drug resistance and management strategies, focusing on the use of protease inhibitors (PIs) and a new generation of integrase strand transfer inhibitors (INSTIs) in second-line treatment.
keywords: Human immunodeficiency virus Antiretroviral therapy Integrase strand transfer inhibitors Drug resistance Raltegravir potassium Elvitegravir Dolutegravir Bictegravir Cabotegravir
文章编号： 中图分类号：R512.91 文献标志码：A
基金项目:
附件
引用文本：
胡志亮，杨永峰.从蛋白酶抑制剂到整合酶抑制剂：HIV耐药管理策略的演变[J].中国临床研究,2025,38(1):87-92.
胡志亮，杨永峰.从蛋白酶抑制剂到整合酶抑制剂：HIV耐药管理策略的演变[J].中国临床研究,2025,38(1):87-92.